Table 1

Distribution of baseline data in the PROGRAMMS cohort

Whole cohortLast previous DMT
NTZaNTZsFTYBasicNaïve
Patients, no1702921335235
Age at baseline ALEM infusion, years, median (IQR)34 (26–41)36 (29–43)34 (31–46)35 (27–42)32 (25–36)27 (22–36)
Male patients, no (%)57 (34)9 (31)2 (10)6 (18)23 (44)17 (49)
Baseline-ARR, median (IQR)1 (1–2)2 (1–2)0 (0–0)1 (1–2)1 (1–2)1 (1–2)
Baseline-EDSS, median (IQR)2.5 (1.5–3.5)3 (2–4)3.5 (2.5–4)3 (2–4)2 (1–3)2 (1–2.5)
Disease duration since onset, years, median (IQR)6 (2–10)9 (7–12)10 (7–15)7 (4–11)5 (3–8)1 (0–2)
Treatment duration of last previous DMT (non-naïve pat.), months, median (IQR)21 (8–37)27.5 (16.75–46.75)21 (7–33)14 (7.5–25)14 (7–34)
Previous DMT
 0 (no (%))35 (21)0 (0)0 (0)0 (0)0 (0)
 1 (no (%))42 (25)5 (17)4 (19)4 (12)29 (56)
 2 (no (%))39 (23)8 (28)9 (43)13 (39)9 (17)
 3 (no (%))31 (18)8 (28)4 (19)9 (27)10 (19)
 ≥4 (no (%))23 (14)8 (28)4 (19)7 (22)4 (8)
Washout duration of last previous DMT, (non-naïve pat.), days, median (IQR)38 (7–51)41 (37–49)56 (46–65)43 (35–67)0 (0–14)
Follow-up duration, months, median (IQR)44 (35–52)39 (29–49)51 (43–65)48 (37.5–54.5)42 (32–50)44 (36–53)
  • Basic treatment group includes patients previously treated with either beta-interferon formulations or dimethyl fumarate.

  • ALEM, alemtuzumab; ARR, annualised relapse rate; DMT, disease-modifying treatment; EDSS, Expanded Disability Status Scale; FTY, fingolimod; NTZa, natalizumab (active subgroup); NTZs, natalizumab (stable subgroup).